-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Therapeutic adaptation: Can treat viral diseases such as seasonal influenza, influenza, influenza A (H1N1), SARS, light and common new coronary virus pneumonia caused by fever, cough, fatigue, muscle soreness, nasal congestion runny nose, headache, dry throat pain, shortness of breath, red tongue, with the effectiveness of detoxification of the lungs.
certificate validity: 5 years Lianhua Qing plague products for the leading products of Ling Pharmaceutical Industry, the national basic drug catalog and the national health insurance catalogue (Class A) varieties, mainly used for the treatment of colds, influenza-related diseases.
Lianhua Qing plague products have been repeatedly included in the National Health and Health Commission, the State Administration of Traditional Chinese Medicine cold, influenza-related disease diagnosis and treatment program.
2020 Lianhua Qing plague capsules/particles are listed as the "New Coronary Company and all members of the Board of Directors to ensure that the information disclosure content is true, accurate and complete, without false records, misleading statements or material omissions."
the pneumonia treatment programme for viral infections (trial version 4/5/6/7/8) recommended medication.
April 12, 2020, the State Drug Administration approved lianhua qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light and common type" on the basis of the original approved adaptation.
2019, the company achieved operating income of 1.703 billion yuan, accounting for 29.24% of the company's total operating income.
first half of 2020, Lianhua Qing plague products achieved operating income of 2,024 million yuan, accounting for 45.11% of the company's total operating income.
So far, Lianhua Qing plague capsules have been registered in Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, Kyrgyzstan and the Philippines as "traditional Chinese medicine", "drug", "plant medicine", "natural health products", "food supplements", "modern plant medicine", "natural medicine" and so on.
announcement, the current overseas sales revenue accounted for a lower proportion of the total revenue of Thering Pharmaceuticals, the company's operating results do not constitute a significant impact.
.